Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

被引:2
|
作者
Halfdanarson, Thorvardur R. [1 ]
Mallak, Nadine [2 ]
Paulson, Scott [3 ]
Chandrasekharan, Chandrikha [4 ]
Natwa, Mona [5 ]
Kendi, Ayse Tuba [1 ]
Kennecke, Hagen F. [6 ]
机构
[1] Mayo Clin, Rochester, MN 55905 USA
[2] Oregon Hlth & Sci Univ, Div Mol Imaging & Therapy, Portland, OR 97239 USA
[3] Texas Oncol, Dallas, TX 75230 USA
[4] Univ Iowa Carver, Coll Med, Iowa City, IA 52242 USA
[5] NYU, Langone Hlth, New York, NY 10016 USA
[6] Providence Canc Inst Franz Clin, Portland, OR 97213 USA
关键词
radioligand therapy; peptide receptor radionuclide therapy; neuroendocrine tumor; response; monitoring; surveillance; positron emission tomography; PET; imaging; somatostatin receptor; RECEPTOR RADIONUCLIDE THERAPY; SOCIETY CONSENSUS GUIDELINES; GA-68-DOTATATE PET/CT; MEDICAL-MANAGEMENT; LU-177-DOTATATE; SURVIVAL; PRRT; HEPATOTOXICITY; Y-90-DOTATOC; PREDICTION;
D O I
10.3390/cancers15194836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Radioligand therapy with [177Lu]Lu-DOTA-TATE is a therapeutic option for adult patients with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients undergoing radioligand therapy require diligent monitoring and surveillance. While published guidelines can provide guidance on general approaches to care, GEP-NETs are heterogeneous and the guidelines can be difficult to apply in individual and complex cases. In this article, we discuss emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving radioligand therapy for GEP-NETs as well as our own best practices. We offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.Abstract Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance
    Scheruebl, Hans
    Cadiot, Guillaume
    VISCERAL MEDICINE, 2017, 33 (05) : 332 - 338
  • [2] Duration of Surveillance for Gastroenteropancreatic Neuroendocrine Tumors
    Chi, Weiwei
    Warner, Richard R.
    Chen, William C.
    Wisnivesky, Juan
    Kim, Michelle K.
    GASTROENTEROLOGY, 2015, 148 (04) : S127 - S127
  • [3] Quality of surveillance in patients with completely resected gastroenteropancreatic neuroendocrine tumors
    Moffat, Gordon Taylor
    Mesci, Aruz
    Chadi, Sami A.
    Jang, Raymond Woo-Jun
    Avery, Lisa
    Moulton, Carol-Anne
    Nathan, Paul C.
    Krzyzanowska, Monika K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 591 - 591
  • [4] Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
    McClellan, Kristen
    Chen, Emerson Y.
    Kardosh, Adel
    Lopez, Charles D.
    Del Rivero, Jaydira
    Mallak, Nadine
    Rocha, Flavio G.
    Koethe, Yilun
    Pommier, Rodney
    Mittra, Erik
    Pegna, Guillaume J.
    CANCERS, 2022, 14 (19)
  • [5] Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Kwekkeboom, Dik J.
    de Herder, Wouter W.
    van Eijck, Casper H. J.
    Kam, Boen L.
    van Essen, Martijn
    Teunissen, Jaap J. M.
    Krenning, Eric P.
    SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) : 78 - 88
  • [6] Radioligand therapy-personalized treatment for patients with neuroendocrine tumors
    Kolasinska-Cwikla, Agnieszka
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (02): : 101 - 109
  • [7] Systemic therapy in the treatment of gastroenteropancreatic neuroendocrine tumors
    Deptala, Andrzej
    Asendrych, Alicja
    Omyla-Staszewska, Joanna
    Rzymkowska, Joanna
    PRZEGLAD GASTROENTEROLOGICZNY, 2006, 1 (01): : 10 - 15
  • [8] Surveillance Patterns of Gastroenteropancreatic Neuroendocrine Tumors at Community and Tertiary Centres
    Watanabe, A.
    McKendry, G. J.
    Yip, L.
    Loree, J.
    Stuart, H. C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S81 - S81
  • [9] Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead
    Sundin, Anders
    Rockall, Andrea
    NEUROENDOCRINOLOGY, 2012, 96 (04) : 261 - 271
  • [10] Gastroenteropancreatic Neuroendocrine Tumors
    Cives, Mauro
    Strosberg, Jonathan R.
    CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (06) : 471 - 487